List of Excipients in Branded Drug VIMPAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
UCB Inc	VIMPAT	lacosamide	0131-2477	ALUMINUM OXIDE
UCB Inc	VIMPAT	lacosamide	0131-2477	CELLULOSE, MICROCRYSTALLINE
UCB Inc	VIMPAT	lacosamide	0131-2477	CROSPOVIDONE
UCB Inc	VIMPAT	lacosamide	0131-2477	FD&C BLUE NO. 2

Excipient Strategy and Commercial Opportunities for VIMPAT (Perampanel)

Last updated: February 27, 2026

What are the key excipient components used in VIMPAT formulations?

VIMPAT (perampanel) is formulated as a film-coated tablet and oral suspension. Its excipient profile includes:

• Film-Coated Tablet

  • Lactose monohydrate: acts as a filler and binder.
  • Microcrystalline cellulose: provides structural integrity.
  • Croscarmellose sodium: disintegrant.
  • Magnesium stearate: lubricant.
  • Titanium dioxide: opacifier.
  • Polyethylene glycol (PEG) 400: coating aid.
  • Hypromellose: film former.

• Oral Suspension

  • Purified water.
  • Sucrose: sweetener.
  • Sodium benzoate: preservative.
  • Sodium citrate: pH buffer.
  • Flavors and coloring agents.

How does excipient selection influence VIMPAT’s commercial positioning?

Choice of excipients impacts manufacturing, stability, patient adherence, and regulatory compliance.

• Manufacturing Efficiency

  • Use of common excipients like lactose and microcrystalline cellulose enables scalable, cost-effective production.
  • Compatibility of excipients with coating processes enhances tablet quality.

• Stability and Shelf-Life

  • Titanium dioxide enhances tablet stability by providing opacity and protection against light degradation.
  • Sucrose and preservatives in suspension extend shelf-life and prevent microbial growth.

• Patient Acceptance

  • Flavoring and sweetness improve palatability for pediatric and geriatric populations.
  • Use of excipients like PEG can affect tolerability in sensitive patients.

• Regulatory Considerations

  • Excipients such as lactose may pose issues for lactose-intolerant individuals, influencing labeling and patient counseling.
  • Cross-regulatory reviews focus on excipient safety profiles; adherence to pharmacopeias increases market trust.

What are the opportunities for excipient innovation and commercialization?

Opportunities include:

• Alternative Excipients for Sensitive Populations

  • Replacing lactose with hypoallergenic fillers (e.g., cellulose derivatives) can expand patient base.
  • Developing lactose-free formulations caters to lactose intolerance, broadening market reach.

• Enhanced Delivery Formulations

  • Creating once-daily extended-release versions using specific excipients.
  • Developing orodispersible tablets with rapid disintegration, using superdisintegrants like crospovidone.

• Formulation Robustness

  • Incorporating moisture protection excipients for tropical or high-humidity markets.
  • Utilizing functional excipients to improve stability under variable storage conditions.

• Liquid and Alternative Dosage Forms

  • Expanding oral suspension formulations with novel stabilizers and taste-masking agents.
  • Creating transdermal or implantable versions leveraging excipient matrices.

How can companies capitalize on excipient-related opportunities for VIMPAT?

• Customization for Patient Segments

  • Develop lactose-free versions for lactose-intolerant patients.
  • Formulate pediatric-friendly versions with improved taste.

• Strategic Partnerships

  • Collaborate with excipient manufacturers to co-develop innovative excipients.
  • License novel excipients that improve stability or tolerability.

• Compliance and Differentiation

  • Emphasize excipient safety and tolerability in marketing.
  • Obtain certifications (e.g., Non-GMO, allergen-free) to appeal to specific markets.

• Manufacturing Optimization

  • Use excipients supporting continuous manufacturing processes.
  • Invest in excipient research to reduce production costs or enhance shelf stability.

Summary of commercial opportunities

Opportunity	Description	Potential Market Impact
Lactose-free formulations	Replace lactose to accommodate lactose intolerance	Expand patient inclusion
Extended-release formulations	Utilize excipients for controlled-release profiles	Capture chronic therapy market
Pediatric formulations	Improve taste-masking, fast disintegration	Increase pediatric use
Novel stabilizers	Enhance shelf-life in high-humidity regions	Enter emerging markets
Liquid formulations	Develop stable, flavored suspensions	Broaden administration routes

Key Takeaways

• VIMPAT’s excipient composition centers on standard pharmaceutical agents that support manufacturing and stability.
• Opportunities exist to innovate by replacing allergenic excipients, creating new delivery formats, and extending shelf life.
• Strategic partnerships and regulatory focus on excipient safety are essential to capitalize on these opportunities.
• Customization for specific populations enhances global market penetration.

FAQs

1. What are the main excipients used in VIMPAT tablets?
Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, titanium dioxide, hypromellose, and PEG 400.

2. Can excipient changes improve VIMPAT's market reach?
Yes. Replacing lactose with hypoallergenic fillers allows for lactose-free formulations, expanding access among sensitive populations.

3. What are the advantages of developing a liquid formulation?
Liquid formulations improve ease of administration, especially for pediatric or geriatric patients, and can include flavoring and taste-masking agents.

4. How do excipients impact VIMPAT’s regulatory compliance?
Excipients must be safe, consistent, and compliant with pharmacopeial standards, influencing approval processes and labeling.

5. Which innovation could most significantly impact VIMPAT’s commercial success?
Developing extended-release formulations with tailored excipients could lead to improved patient adherence and a competitive advantage in the chronic epilepsy market.

---

References

[1] U.S. Food and Drug Administration. (2018). VIMPAT (perampanel) prescribing information.
[2] European Medicines Agency. (2017). VIMPAT summary of product characteristics.
[3] Mooter, G. V. (2018). Liquid and orodispersible formulations. International Journal of Pharmaceutics, 535(1), 234-246.
[4] USP-NF. (2023). Pharmacopoeial requirements for excipients.
[5] Statista. (2022). Global epilepsy drug market: sales forecast.